Texas Biomed Partners With U.S. Defense to Counter Biological Threats

The partnership with the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND) focuses on refining the testing and validation of life-saving treatments. By leveraging Texas Biomed’s high-containment laboratories and adherence to strict Good Laboratory Practice standards, the collaboration seeks to bridge the gap between initial scientific discovery and regulatory approval by the FDA.

Cory Hallam, Executive Vice President of Applied Science & Innovation at the institute, emphasized the necessity of shortening the timeline from lab-based insight to real-world application. The agreement provides a permanent structure for resource availability, shifting away from episodic responses to biological risks toward a model of constant readiness. As Larry Schlesinger, President and CEO of Texas Biomed, noted, the collaboration serves as a long-term investment in national resilience against evolving pathogens.